# Best Buy Co. Inc. (BBY) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BBY/thesis · /stocks/BBY/memo

## Financial Snapshot

---
source: coverage-next-full
step: 04
title: Financial Quality & Adversarial Sweep
ticker: BBY
date: 2026-05-27
---

### Step 04 — Financial Quality & Adversarial Sweep: Best Buy Co. Inc. (BBY)

#### 1. Financial Statement Quality Assessment

##### Income Statement
**Quality: High.** Best Buy's income statement is straightforward for a large-cap retailer. Revenue recognition is standard (point of sale for products; ratably for service plans/subscriptions). No unusual off-balance-sheet revenue arrangements detected. The company presents both GAAP and non-GAAP (adjusted) metrics — adjusted EPS excludes restructuring charges, goodwill impairments, and discrete tax items.

**GAAP vs. Adjusted EPS (FY2025-FY2026):**
- FY2025 GAAP EPS: $4.28 vs. Adjusted: ~$6.06 (large gap due to Health goodwill impairment ~$475M)
- FY2026 GAAP EPS: $5.04 vs. Adjusted: $6.43 (gap = ~$293M pretax adjustments, primarily restructuring)

The gap between GAAP and adjusted is material (~$1.39/share in FY2026) and investors should monitor the nature of exclusions. [JUDGMENT] The Health-related impairments (FY2025 and FY2026) are genuine economic costs — the Best Buy Health acquisitions destroyed capital. [S3]

##### Balance Sheet
**Quality: High.** Balance sheet is clean and straightforward.

Key observations:
- **Operating leases:** ~$2.3B non-current operating lease liability [S1] — represents the primary fixed-cost commitment of the store base. This is not debt but behaves like it in stress scenarios.
- **Goodwill:** Declined from $1.38B (FY2023-FY2024) to $0.91B (FY2025) to $0.79B (FY2026) — ~$590M of impairments over 2 years [S1]. Best Buy Health is the likely culprit (GreatCall/Lively/Current Health acquisitions).
- **Inventory:** $5.23B as of January 31, 2026 [S1] — representative of seasonal post-holiday level. Inventory turns are ~6x annually, consistent with electronics retail.
- **Accounts payable:** $4.75B vs. inventory $5.23B — payables are ~91% of inventory, representing significant vendor financing. [S1]
- **Net debt:** ($1.74B cash - $1.17B LTD) = net cash ~$0.57B excluding operating leases [S1]

##### Cash Flow Statement
**Quality: High.** Operating cash flow ($1.96B FY2026) is healthy and consistently above net income, driven by non-cash charges (D&A $831M, SBC $139M, lease amortization) and working capital benefits. [S1]

**Free Cash Flow trend:**
| FY | OCF | Capex | FCF | FCF Margin |
|----|-----|-------|-----|-----------|
| FY2022 | 3,252 | (737) | 2,515 | 4.9% |
| FY2023 | 1,824 | (930) | 894 | 1.9% |
| FY2024 | 1,470 | (795) | 675 | 1.6% |
| FY2025 | 2,098 | (706) | 1,392 | 3.4% |
| FY2026 | 1,962 | (704) | 1,258 | 3.0% |

FY2022 OCF was inflated by massive payables build during supply-chain surge. FY2024 trough reflects COVID reversal and higher capex. FY2025-FY2026 stabilization is genuine. [FACT]

#### 2. Accounting Adjustments

**No material adjustments required.** Best Buy's accounting is conservative and GAAP-based.

Adjustments analysts commonly make:
1. **Capitalize operating leases** (add ~$2.3B to debt-equivalent; reduce EBIT by implied interest): Relevant for EV/EBITDA calculations
2. **Exclude Health impairments** from normalized EPS: Legitimate — these are non-cash and one-time
3. **Normalize tax rate** to ~24% (FY2025's 28.7% was elevated by deferred tax effects on goodwill impairment): FY2026 normalizes

#### 3. Adversarial Research Sweep

**This section follows the filings-and-consensus path. Transcript analysis not performed per coverage-next-full methodology.**

##### Short Interest & Bearish Theses
- Short interest on BBY is not unusually elevated as of May 2026. The stock has been a value/income name, not a short target.
- Primary bearish thesis: Structural revenue decline, Amazon share gains, and margin compression — all well-known and extensively documented.
- No active short sellers publishing reports calling out accounting fraud or concealment.

##### Legal / Regulatory
- No material litigation disclosed in recent 10-K filings beyond routine consumer, employment, and IP matters typical for a large retailer.
- TCPA (telemarketing) class action risk exists for retail media/loyalty communications; no material active case noted.
- Right-to-repair legislation (state level): Some risk to services revenue model if consumers gain easier repair access elsewhere; not yet material.

##### Corporate Governance Concerns
- **CEO succession:** Barry → Bonfig announced April 22, 2026; effective October 31, 2026 [S4]. Internal promotion from Chief Customer Officer. Governance risk: Limited; orderly succession.
- **Best Buy Health acquisition track record:** ~$590M in goodwill impairments (FY2025–FY2026) on Health acquisitions is a capital allocation failure. GreatCall (~$800M, 2018), Current Health (est. ~$400M, 2021), Lively/Caring Center brands all appear to have underperformed. [JUDGMENT based on impairment data] [S1]
- **Vendor concentration:** Top 5 vendors = ~55% of merchandise. Apple alone is likely >15% of total merchandise. Loss of a major vendor relationship (or vendor going direct) would be material. [S2]

##### Related-Party or Off-Balance-Sheet Issues
- No material related-party transactions disclosed beyond standard executive compensation arrangements.
- Operating leases are now on-balance-sheet under ASC 842; no meaningful off-balance-sheet obligations identified.

##### Supply Chain / Geopolitical
- ~30-35% of COGS from China-sourced products [S3]. US-China tariff regime creates ongoing input cost risk.
- Best Buy has been diversifying away from China since 2018 (from ~55% estimated then); progress evident but not complete.

##### Channel & Pricing Integrity
- Price-match guarantee is a competitive necessity but limits upside margin capture.
- No evidence of channel-stuffing or revenue recognition issues.

#### 4. Overall Financial Quality Verdict

**Verdict: CLEAN — Investment Grade Quality**
- Accounting is conservative and transparent
- Cash flow quality is high (OCF > Net Income consistently)
- No material red flags in adversarial sweep
- The one caution: GAAP/adjusted gap is material (~$1.40/share FY2026); investors should monitor Health-related charges and restructuring for signs of recurring "non-recurring" items
- Best Buy Health acquisition was a capital misallocation; impairments are the honest acknowledgment of this; ongoing monitoring warranted

#### Source Index
- [S1] SEC EDGAR XBRL — financial data — retrieved 2026-05-27
- [S2] Best Buy FY2026 10-K highlights (StockTitan) — retrieved 2026-05-27
- [S3] Web search — tariff exposure, competitive landscape — retrieved 2026-05-27
- [S4] SEC 8-K CEO succession announcement — retrieved 2026-05-27

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BBY/fundamental

## Navigation

- Overview: /stocks/BBY
- Financials (this page): /stocks/BBY/financials
- Thesis: /stocks/BBY/thesis
- Investment Memo: /stocks/BBY/memo
- Coverage universe: /stocks